Celularity
Update in progressCELU (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Celularity Inc. is a regenerative and cellular medicines company focused on aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapies, including mesenchymal-like cells, for conditions like diabetic foot ulcers and Crohn’s disease. It operates in Cell Therapy, Degenerative Disease, and BioBanking, with programs PDA-001, PDA-002, and pExo-001, plus wound-care products and LifebankUSA banking. It partners with Sorrento for CD19 CAR-T and with Regeneron for allogeneic cell therapy research. Founded 1998, Florham Park, NJ.
Company score
- Sentiment
- 0.28
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.03
- Governance
- 0.08
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.01
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.14
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEODr. Robert Joseph Hariri M.D., Ph.D.
- Founded1998
- Employees115
- Websitewww.celularity.com
Identifiers
- ISINUS1511901050
- FIGIBBG00P2RTT34
- CUSIP151190105
- CIK0001752828